



ASX ANNOUNCEMENT

Actinogen Medical participating in the BIO 2019 Convention

- **Actinogen Medical to participate in BIO 2019 Convention in Philadelphia, 3-6 June 2019**
- **The BIO 2019 International Convention brings together over 4000 global biotech and pharma companies, from nearly 80 countries, facilitating extensive partnering and networking opportunities across the industry**

Sydney, 3 June 2019. Actinogen Medical ASX: ACW ('ACW' or 'the Company') will attend the BIO 2019 International Convention in Philadelphia from the 3-6 June and participate in a number of partnering meetings with major international pharmaceutical companies. BIO International is the world's largest biotech partnering event and attracts over 4,000 biotechnology and pharma companies from nearly 80 countries, facilitating extensive partnering and networking opportunities across the industry.

Actinogen will be meeting with numerous major pharmaceutical companies to discuss the clinical development program for Xanamem™, insights into the positive safety and pharmacodynamic results from the XanADu trial, and the progress the Company is making with the nine additional studies initiated over the past 12 months, including the XanaHES dose escalation study and the target occupancy study. The Company will also be discussing the planned new indications for Xanamem: cognitive impairment in mood disorders including bipolar disorder, and schizophrenia.

Actinogen CEO Dr Bill Ketelbey, said the outcomes and learnings from the XanADu trial, particularly the positive safety and pharmacodynamic data, are of interest to the pharmaceutical industry.

"We have a large number of meetings lined up with big pharma, demonstrating the level of interest in Xanamem as a novel treatment for Alzheimer's disease, and the cognitive impairment associated with a broad range other neurological conditions. These potential partners have been following our progress for some time and we now have a comprehensive suite of safety data and evidence of Xanamem's pharmacodynamics effects, generated in the XanADu trial, to share."

Actinogen Medical expects additional results from current Xanamem studies by the end of June 2019 and subsequently will provide an update to shareholders on the findings from these studies, to inform the next stage of Xanamem's development.

ENDS

Actinogen Medical

Dr. Bill Ketelbey
CEO & Managing Director
P: +61 2 8964 7401
E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

Investor and Media Enquiries

Arthur Chan
WE Buchan
M: +61 2 9237 2805
E: arthurc@we-buchan.com

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotechnology company focused on innovative approaches to treating cognitive decline that occurs in chronic neurological and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with multibillion-dollar market potential and material human impact. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn and is projected to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia. In addition, Actinogen is currently planning an expanded clinical development program for Xanamem in cognitive impairment in mood disorders and schizophrenia. In the US alone, the collective economic costs of mood disorders and schizophrenia are estimated to exceed \$550bn, with the burden increasing every year. The cognitive dysfunction associated with these conditions is significantly debilitating for affected patients, with a substantial unmet medical need for novel, improved treatments.

About Xanamem™

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory. The 11β-HSD1 enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain associated with cognitive impairment in neurological diseases, including Alzheimer's disease, mood disorders and schizophrenia.

About XanADu

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu has fully enrolled 186 patients from 25 research sites across Australia, the UK and the USA. The trial is registered on www.clinicaltrials.gov with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

About XanaHES

XanaHES is a Phase I, randomised, single blinded, central reader blinded, placebo-controlled, dose escalation study to assess the safety and tolerability of Xanamem™ 20mg & 30mg once daily in healthy elderly volunteers. Changes in cognitive performance from baseline to end-of-treatment will be measured as an exploratory efficacy outcome.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.